STAT+: Another big deal, another sign biotech M&A is back

STAT+ reported that pharmaceutical companies are actively engaging in mergers and acquisitions within the biotechnology sector, signaling a resurgence in biotech M&A activity. This trend is underscored by significant deals and a general increase in acquisition interest. The article also highlights promising late-stage clinical trial data for an LSD-based pill, which has shown unusually strong results in treating depression. Furthermore, the U.S. Food and Drug Administration (FDA) has altered its stance on Regenxbio's therapeutic treatment, indicating a shift in regulatory review or approval pathways. These developments are occurring as thousands of industry professionals convene in San Diego for the BIO conference, a major event for discussing deals, scientific advancements, and future industry directions. The BIO conference is a significant gathering for networking and deal-making in the life sciences industry.